Study The study in question is the ALCYONE Trial, published in NEJM in 12 December 2017 by María-Victoria Mateos, Meletios A Dimopoulos, et al.
The investigators studied the effect of adding Daratumumab with Bortezomib, Melphalan and Prednisolone in patients with freshly detected Myeloma ineligible for Autologous Bone Marrow Transplantation.
The study arms were Arm 1: Daratumumab + Bortezomib + Melphalan + Prednisolone and Arm 2: Bortezomib + Melphalan + Prednisolone